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Autophagy is a catabolic lysosomal degradation process essential for cellular homeostasis and cell survival.
Dysfunctional autophagy has been associated with a wide range of human diseases, e.g., cancer and
neurodegenerative diseases. A large number of small molecules that modulate autophagy have been widely used to
dissect this process and some of them, e.g., chloroquine (CQ), might be ultimately applied to treat a variety of
autophagy-associated human diseases. Here we found that vacuolin-1 potently and reversibly inhibited the fusion
between autophagosomes and lysosomes in mammalian cells, thereby inducing the accumulation of autophagosomes.
Interestingly, vacuolin-1 was less toxic but at least 10-fold more potent in inhibiting autophagy compared with CQ.
Vacuolin-1 treatment also blocked the fusion between endosomes and lysosomes, resulting in a defect in general
endosomal-lysosomal degradation. Treatment of cells with vacuolin-1 alkalinized lysosomal pH and decreased
lysosomal Ca2C content. Besides marginally inhibiting vacuolar ATPase activity, vacuolin-1 treatment markedly
activated RAB5A GTPase activity. Expression of a dominant negative mutant of RAB5A or RAB5A knockdown
significantly inhibited vacuolin-1-induced autophagosome-lysosome fusion blockage, whereas expression of a
constitutive active form of RAB5A suppressed autophagosome-lysosome fusion. These data suggest that vacuolin-1
activates RAB5A to block autophagosome-lysosome fusion. Vacuolin-1 and its analogs present a novel class of drug that
can potently and reversibly modulate autophagy.
Introduction
Among 3 types of autophagy, including microautophagy,
chaperone-mediated autophagy, and macroautophagy, in mam-
mals, macroautophagy (hereafter referred as autophagy) is the
most common type. Autophagy is an evolutionarily conserved
catabolic degradation cellular process in which misfolded pro-
teins or damaged organelles are first sequestered by a double-
membrane vesicle, called an autophagosome. Autophagosomes
then fuse with lysosomes to form autolysosomes, inside which
the sequestered contents are digested by lysosomal enzymes and
recycled to maintain cellular homeostasis. Autophagy can also be
markedly induced by a wide variety of stresses, e.g., nutrient star-
vation, infection, and aging, for cell survival. Dysfunctional
autophagy has been associated with wide ranges of human dis-
eases, e.g., cancer and neurodegenerative diseases.1-6
Basal autophagy activity is essential for cell homeostasis, and it
is tightly controlled by a complicated interplay among several key
machineries, including ULK1 or ULK2 complexes and the class
III phosphatidylinositol-3 kinase complexes. The MTOR (mech-
anistic target of rapamycin) Ser/Thr kinase suppresses autophagy
by inhibiting the ULK1/2 complex. Starvation, on the other
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hand, activates the AMPK (AMP-activated protein kinase) to
inactivate MTOR, thereby inducing autophagy. The lipidation
of the MAP1LC3 (microtubule-associated protein 1 light chain
3) (herein referred simply as LC3) is essential for autophagy
induction as well. The conjugation of phosphatidylethanolamine
(PE) to LC3 is sequentially controlled by the protease autoph-
agy-related (ATG) 4, E1-like enzyme ATG7, and the E2-like
enzyme ATG3, thereby converting the cytosolic LC3 (LC3-I) to
the autophagic vesicle-associated form (LC3-II). Notably, lipi-
dated LC3-II shows a punctate staining pattern and has faster
electrophoretic mobility compared with diffused LC3-I.1,7
Although enormous progress has been made on the core molecu-
lar machineries of autophagy, mechanisms of autophagy induc-
tion, autophagosome maturation, and autophagosome-lysosome
fusion still remain elusive in mammalian cells.8
RAB5, a small GTPase, is essential for endolysosomal system
biogenesis, and RAB5 knockdown markedly reduced the number
of early endosomes, late endosomes, and lysosomes, accompanied
with a blockage in endocytosis of low-density lipoprotein. More-
over, RAB5-to-RAB7 conversion, aided by the class C VPS
HOPS complex, is required for early and late endosomes progres-
sion.9-13 In addition, RAB5 was found to be involved in autoph-
agy by regulating PIK3C3/VPS34 activity likely via PIK3CB/
p110beta, a catalytic subunit of the class IA phosphoinositide 3-
kinase, in response to growth factor limitation.14 Yet the precise
role of RAB5 in autophagy regulation remains to be
determined.15,16
Not surprisingly, a large number of chemicals either promote
or inhibit autophagy. Some of these compounds have been
widely used to dissect the mechanisms underlying autophagy.17
Popular autophagy inducers include MTOR kinase inhibitors,
e.g., rapamycin and torin 1,18 and chemicals inhibiting inositol
monophosphatase, e.g., lithium and carbamazepine.19 Notably,
rapamycin is an immunosuppressant and has recently been used
as an anticancer agent.20 Lithium has been used to treat Hunting-
ton disease and other related neurodegenerative disorders.21
Commonly used autophagy inhibitors include chloroquine
(CQ), 3-methyladenine, wortmannin, and bafilomycin A1
(BAF).17,22-24 Higher basal autophagic activity detected in estab-
lished tumor cells is found to promote the survival and growth of
tumors by maintaining energy production under increased meta-
bolic consumption and a hypoxic microenvironment, thereby
enabling tumors escape chemotherapy and/or radiation.25 There-
fore, numerous preclinical studies have found that inhibition of
autophagy by CQ restores chemosensitivity and promotes tumor
cell death by diverse anticancer therapies.26 Recently, many new
autophagy chemical modulators have been identified by image-
based screens with GFP-LC3 transfected cells. Although these are
useful pharmacological tools to study autophagy and are poten-
tial therapeutic drugs for autophagy-related diseases, many of
these compounds lack specificity, or potency, or both.27 There-
fore, the search for specific and potent autophagy chemical mod-
ulators must continue in order to gain deep insight of autophagy
and provide potential therapeutic drugs.
Here we found that vacuolin-1 potently and reversibly inhib-
ited the fusion between autophagosomes and lysosomes, thereby
inducing the accumulation of autophagosomes. This effect is
likely due to vacuolin-1-induced RAB5A activation, vacuolar
ATPase activity inhibition, and the subsequent lysosomal pH
alkalinization. Amazingly, vacuolin-1 was much less toxic but at
least 10-fold more potent in inhibiting autophagy compared
with CQ.
Results
Vacuolin-1 inhibited autophagosome-lysosome fusion in
HeLa cells
Prompted by the fact that many available autophagy chemical
modulators lack either potency or specificity,26 we set up a fluo-
rescence image-based assay to screen molecules affecting autoph-
agy. To do so, we infected HeLa cells, an autophagy competent
cell line, with lentiviruses carrying expression cassettes that
encode tandem fluorescence-tagged LC3B (tfLC3B).28 Thus, the
LC3-II positive autophagosomes are labeled with both GFP and
RFP signals shown as yellow puncta, and after fusion with lyso-
somes, autolysosomes are shown as red only puncta because GFP
loses its fluorescence in acidic pH. As shown in Figure S1, starva-
tion greatly induced the increase of both yellow and red
only puncta, yet treatment of cells with BAF, an inhibitor of the
vacuolar proton pump that blocks the fusion of autophagosomes
with lysosomes,29 or CQ markedly induced the accumulation
of yellow puncta only, indicating that the autophagy is
arrested at autophagosomes. These data indicate that tfLC3B-
expressing HeLa cells can be used to monitor the progression of
autophagy.
Next, we selected a panel of molecules that are commercially
available and have been previously shown to affect vesicle traffick-
ing or organelle morphology, and screened their effects on
autophagy regulation in tfLC3B-expressing HeLa cells (data not
shown). One molecule, vacuolin-1, potently induced LC3B yel-
low puncta, not red only puncta (Fig. 1A; Fig. S1). Western blot
analyses further confirmed that lipidated LC3B-II was markedly
increased in cells treated with vacuolin-1. SQSTM1/p62, an
autophagic substrate,30 was also accumulated in cells treated with
vacuolin-1, suggesting that vacuolin-1 inhibits the fusion
between autophagosome and lysosomes (Fig. 1B). Indeed, GFP-
LC3B puncta were greatly increased in vacuolin-1 treated cells
and did not colocalize with lysosome-associated membrane pro-
tein 1 (LAMP1) (Fig. 1C), which was similar to the cells treated
with BAF (Fig. S2). On the other hand, the majority of RFP-
LC3B puncta induced by vacuolin-1 were colocalized with
STX17-GFP, an autophagosome marker (Fig. S3).31,32 Similarly,
vacuolin-1 induced the accumulation of both LC3B-II and
SQSTM1 in the presence of autophagy inducer, starvation, or
rapamycin (Fig. S4; Fig. 1C). To further exclude the possibility
that accumulated LC3B-II or SQSTM1 is the result of inactiva-
tion of lysosomal proteases, we treated cells with leupeptin
(leup), a protease inhibitor, in the presence or absence of vacuo-
lin-1. As expected, vacuolin-1 treatment blocked the accumula-
tion of autolysosomes induced by leup (Fig. S5), and
cotreatment of cells with vacuolin-1 and leup only marginally
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increased the accumulation of
LC3B-II and SQSTM1 com-
pared with vacuolin-1 treat-
ment alone (Fig. S6).
Moreover, under the electron
microscope, large numbers
of autophagosomes were
observed in vacuolin-1 treated
HeLa cells maintained in nor-
mal culture conditions
(Fig. 1D). Taken together,
these data clearly demon-
strated that vacuolin-1, similar
to BAF or CQ, blocks the
fusion between autophago-
somes and autolysosomes,
thereby leading to accumula-
tion of LC3B-II positive
autophagosomes.
Vacuolin-1 potently and
reversibly inhibited
autophagy but showed little
cell toxicity
Vacuolin-1 is a cell-perme-
able and water-soluble triazine
based compound. It has been
previously reported that vacuo-
lin-1 induced rapid homotypic
fusion of endosomes and lyso-
somes to form large and swol-
len structures, yet it did not
disturb cell cytoskeletal net-
work.33-35 Amazingly, vacuo-
lin-1 was at least 10 times
more potent than CQ in sup-
pressing autophagy (Fig. 2A;
Fig. S7), yet it exhibited much
less cell toxicity than CQ in a
wide variety of cell types
(Fig. 2B; Fig. S8). Interest-
ingly, the fusion block between
autophagosomes and lysosomes
was completely relieved 3 h
after removal of vacuolin-1
from the medium (Fig. 2C).
Similarly, vacuolin-1 induced
homotypic fusion between
endosomes or lysosomes was
recovered after removal of
vacuolin-1 (data not shown).
These data indicate that the
effects of vacuolin-1 on
autophagy inhibition or homo-
rtypic fusion are reversible.
Figure 1. Vacuolin-1 inhibited the fusion between autophagosomes and lysosomes in HeLa cells. (A) Vacuolin-1
induced the accumulation of yellow LC3-II puncta in tfLC3B-expressing HeLa cells. Scale bar: 20 mM. Quantifica-
tion of LC3 yellow puncta/red puncta (%) is expressed as mean § S.E., n D »80 cells of 3 independent experi-
ments. (B) Vacuolin-1 (1 mM) induced the accumulation of both LC3B-II and SQSTM1 in HeLa cells. (C) Vacuolin-1
(1 mM) markedly induced GFP-LC3B-II puncta in HeLa cells, which were not colocalized with RFP-LAMP1. Scale
bar: 20 mM. The GFP-LC3B and LAMP1 colocalization coefficiency is expressed as mean § S.E., n D »80 to 100
cells of 4 independent experiments. (D) Vacuolin-1 (1 mM) induced the accumulation of autophagic vacuoles as
shown in the electron micrographs and highlighted in areas D1 and D2. Quantification of autophagosomes per
cell are expressed as mean§ S.E., nD»20 to 40 cells. The *symbols indicate the results of the Student t test anal-
ysis, P < 0.05.
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Vacuolin-1 alkalinized lysosomal pH and decreased
lysosomal Ca2C content
We then explored the mechanisms underlying vacuolin-1-
induced autophagy arrest. As lysosomal pH is essential for the
fusion36 and lysosomes were enlarged by vacuolin-1 treatment,33-35
we examined whether vacuolin-1 affects lysosomal pH in these
enlarged lysosomes. We first applied LysoSensor Green DND-189
(pKa D »5.2) to qualitatively measure lysosomal pH.37
Figure 2. Vacuolin-1 reversibly inhibited autophagy by increasing lysosomal pH in HeLa cells. (A) Vacuolin-1 was a more potent autophagy inhibitor than
CQ. Cells were treated with vacuolin-1 or CQ at the indicated dose for 6 h, and western blot analyses against LC3B and SQSTM1 were then performed.
100 mM CQ induced great cell loss is indicated by *. (B) Vacuolin-1 had much less cell toxicity than CQ in HeLa cells. Cells were treated with vacuolin-1 or
CQ for the indicated doses for 48 h, and cell viability was then determined by MTT assay. (C) Vacuolin-1 (1 mM) reversibly inhibited autophagy. (D and E)
Vacuolin-1 (1 mM) induced an increase of lysosomal pH in HeLa cells as determined by microplate reader measurement of Lysosensor DND-189 stained
cells (D) or by a quantitative ratiometric LysoSensor Yellow/Blue DND-160 stained cells (E). (F) Vacuolin-1 (1 mM) pretreatment for 5 h markedly inhibited
the ability of GPN (200 mM) to release lysosomal Ca2C in Fura-2 loaded HeLa cells in the absence of extracellular Ca2C. The graphs in (B, D, E, or F) repre-
sent data from 3 independent experiments, and data are expressed as mean § S.D., n D 3. The * symbols indicate the results of the Student t test analy-
sis, P < 0.05.
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LysoSensor Green DND-189 permeates cell membranes and accu-
mulates in acidic intracellular organelles, and its fluorescence
increases or decreases in acidic or alkaline environments, respectively.
As shown in Figure 2D, vacuolin-1 treatment raised lysosomal pH
inHeLa cells.We further quantified lysosomal pH using quantitative
ratiometric LysoSensor Yellow/Blue DND-16038-stained cells, and
found that lysosomal pH in vacuolin-1-treated HeLa cells was
increased from pH 4.7 in control cells to pH 5.2 (Fig. 2E). Thus, it
is clear that vacuolin-1 alkalinizes lysosomal pH.
Since lysosomes represent a major intracellular Ca2C pool and
Ca2C and protons are tightly coupled in lysosomes,39 we also
assessed whether vacuolin-1 treatment affects the lysosomal Ca2C
content. Treatment of cells with glycyl-l-phenylalanine 2-naph-
thylamide (GPN) selectively disrupts the lysosomal membrane,40
thereby releasing the lysosomal Ca2C.41 As shown in Figure 2F,
pretreatment of cells with vacuolin-1 significantly lowered the
ability of GPN to induce lysosomal Ca2C release, suggesting that
vacuolin-1 decreases lysosomal Ca2C levels as well.
Vacuolin-1 inhibited general endosomal-lysosomal
degradation in HeLa cells
Since the increase of lysosomal pH normally compromises the
lysosomal activity, we assessed whether vacuolin-1 affects the gen-
eral lysosomal functions to inhibit autophagy maturation. The
processing of CTSL (cathepsin L) from the precursor form to its
mature form has been commonly used as a marker for lysosomal
activity,42 and we found that the processing of CTSL into its
mature form was not affected in vacuolin-1-treated HeLa cells,
but vacuolin-1 did markedly increase the levels of immature
form of CTSL (Fig. 3A). Similarly, treatment of cells with vacuo-
lin-1 for 6h did not change the processing of CTSB (cathepsin B)
(Fig. S9).42 These data indicate that the subtle increase of lyso-
somal pH induced by vacuolin-1 does not affect lysosomal prote-
ase activity.
Next, an EGFR (epidermal growth factor receptor) degrada-
tion assay was performed to examine whether vacuolin-1 affects
the general endosomal-lysosomal pathway. In this assay, HeLa
cells were treated with EGF in the presence or absence of vacuo-
lin-1. After EGF binds to its receptors, the receptor complex
undergoes endocytosis and is targeted to lysosomes for degrada-
tion. As shown in Figure 3B, vacuolin-1 inhibited EGF-triggered
EGFR degradation. Interestingly, EGFR was internalized nor-
mally but the endosomes containing EGFR failed to fuse with
lysosomes; this explains the accumulation of EGFR in vacuolin-1
treated cells (Fig. 3C). Similarly, a DQ-BSA-green degradation
assay was applied to measure the general endosomal-lysosomal
degradation. DQ-BSA-green is a BSA labeled with a self-
quenching fluorescent dye. After DQ-BSA-green is delivered to
lysosomes via endocytosis, it is hydrolyzed into single dye-labeled
peptides by lysosomal proteases, thereby relieving self-quenching
and the fluorescence can subsequently be monitored by flow
cytometry. As shown in Figure 3D, vacuolin-1 markedly inhib-
ited the degradation of BSA by lysosomes, yet DQ-BSA-Green
was present in endosomes but failed to be delivered to lysosomes
(data not shown). Collectively, these results support that vacuo-
lin-1 inhibits the general endosomal-lysosomal degradation,
which is most likely because the alkalized lysosomal pH stops the
fusion of endosomes with lysosomes.
We then assessed whether vacuolin-1 inhibits V-ATPase activ-
ity to increase lysosomal pH. Vacuolin-1 at concentration of
1 mM resulted in »30% inhibition of V-ATPase activity, yet
higher concentration of vacuolin-1 failed to further inhibit it
(Fig. 3E). Since hydrophobic substances at high concentrations
sometimes have disturbing/inhibitory effects on the ATPase
activity,43 the observed small inhibition of V-ATPase by high
concentrations of vacuolin-1 is likely nonspecific. On the other
hand, the ATPase activity dropped sharply from 100% to 0%
within a concentration range of a factor of 100 for BAF, a potent
V-ATPase inhibitor with IC50 D 3 nM (Fig. 3E). Taken
together, these data suggest that vacuolin-1 is a weak V-ATPase
inhibitor.
RAB5A was required for vacuolin-1-induced autophagy
arrest and endosomal fusion
Vacuolin-1 also induced the homotypic fusion of endosomes
or lysosomes, and RAB5, a small GTPase, is essential for endo-
some fusion.11 We thus examined whether vacuolin-1 activates
RAB5 to regulate autophagy. Indeed, vacuolin-1 markedly acti-
vated RAB5, as shown by a GST-tagged RABEP1/RABaptin5
affinity isolation assay, which specifically interacts with RAB5-
GTP, not RAB5-GDP (Fig. 4A).44 Consistently, RAB5A knock-
down markedly decreased vacuolin-1-induced accumulation of
both LC3B-II and SQSTM1 (Fig. 4B–D). Similarly, overexpres-
sion of a dominant-negative form of RAB5A (RAB5A-DN)
blocked vacuolin-1-induced autophagy arrest and homotypic
fusion, whereas overexpression of a constitutive active form of
RAB5A (RAB5A-CA)45 augmented the ability of vacuolin-1 to
induce autophagy arrest and homotypic fusion (Fig. 4E and F).
Interestingly, RAB5A-CA overexpression alone also inhibited the
autophagosome-lysosome fusion, thereby inducing the accumu-
lation of LC3B-II and SQSTM1 (Fig. 4G; Figs. S10 and S13).
Notably, RAB5A-DN expression or RAB5A knockdown did not
affect starvation-induced autophagy (Fig. 4C and D; Figs. S11
and S12). Taken together, these data indicate that RAB5A is
required for vacuolin-1-induced autophagy arrest.
Discussion
Here we found that vacuolin-1 potently and reversibly inhib-
ited autophagosome-lysosome fusion, thereby accumulating
autophagosomes (Fig. 1; Figs. S1–S6). Although vacuolin-1 is at
least 10 times more potent than CQ in inhibiting autophagy
(Fig. 2A; Fig. S7), vacuolin-1 showed much less cell toxicity
than CQ (Fig. 2B; Fig. S8). Vacuolin-1 alkalized lysosomal pH
(Fig. 2D and E) and decreased lysosomal Ca2C content
(Fig. 2F), but vacuolin-1 only weakly and nonspecifically inhib-
ited V-ATPase (Fig. 3E). On the other hand, vacuolin-1
markedly activated RAB5 (Fig. 4A), and expression of RAB5A-
DN or RAB5A knockdown significantly inhibited vacuolin-1-
induced autophagosome accumulation (Fig. 4B–F). We specu-
late that RAB5A activation by vacuolin-1 indirectly contributes
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Figure 3. Vacuolin-1 inhibited general endosomal-lysosomal degradation in HeLa cells. (A) The processing of CTSL from the precursor form to its mature
form in HeLa cells treated with or without vacuolin-1 (1 mM) or BAF (100 nM). (B) Vacuolin-1 (1 mM) inhibited EGF-induced EGFR degradation in HeLa
cells. (C) Vacuolin-1 (1 mM) inhibited the fusion of EGFR endosomes with lysosomes in HeLa cells. Scale bar: 20 mM. The EGF-488/LAMP1 colocalization
coefficiency is expressed as mean § S.E., n D »40 cells of 2 independent experiments. (D) Vacuolin-1 (1 mM) inhibited the degradation of DQ-BSA-Green
in HeLa cells. (E) Vacuolin-1 nonspecifically inhibited V-ATPase as assessed by the in vitro V-ATPase assay, whereas BAF markedly inhibited it. The activity
of V-ATPase (1.05 § 0.09 mmol/min/mg) at 0 mM of inhibitors is set to 100%. The data are expressed as mean § S.D., n D 3. The * symbols indicate the
results of the Student t test analysis, P < 0.05.
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Figure 4. RAB5A is required for vacuolin-1-induced autophagy arrest and homotypic fusion in HeLa cells. (A) Vacuolin-1 (1 mM) activated RAB5A in HeLa
cells. The active RAB5A in cells treated with vacuoin-1 or transfected with RAB5A-CA or RAB5A-DN were examined by a GST-tagged RABEP1 affinity isola-
tion assay. Quantification of RAB5A-GTP/total RAB5A (relative fold) is expressed mean § S.D., n D 3. (B) RAB5A knockdown blocked vacuolin-1-induced
accumulation of LC3B-II and SQSTM1 in HeLa cells. Quantifications of LC3B-II/GAPDH and SQSTM1/GAPDH (relative fold) are expressed mean § S.D.,
n D 4. (C) RAB5A knockdown blocked GFP-LC3 puncta induced by vacuolin-1 (1 mM) but not by starvation in HeLa cells. (D) Quantification of GFP-LC3B
puncta/per cell in (C) is expressed as mean § S.E., n D »50 to 60 cells of 3 independent experiments. The * symbols indicate the results of the Student t
test analysis, P < 0.05. (E) Expression of RAB5A-CA enhanced vacuolin-1-induced autophagy arrest, whereas expression of RAB5A-DN blocked it in HeLa
cells. (F) Data quantifications of GFP-LC3B puncta/per cell in (E) are expressed as mean § S.E., n D »80 cells of 3 independent experiments. (G) Expres-
sion of RAB5A-CA alone induced the accumulation of LC3-II as assessed by western blot analyses (representative of 3 independent experiments).
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to the increase of lysosomal pH, thereby compromising normal
lysosomal functions, including autophagasome-lysosome fusion
and endosomal-lysosomal degradation.
Vacuolin-1 was originally found to induce homotypic fusion
of endosomes or lysosomes, thereby forming large vacuoles. Yet,
it does not alter other cell structures and membrane-trafficking
functions.33-35 It remains controversial whether vacuolin-1
blocks the Ca2C-dependent exocytosis of lysosomes. One study
suggests that the effects of vacuolin-1 on lysosomal exocytosis
depend on the cell types and mode of activation.33 Interestingly,
Cerny et al. have found that some enlarged vacuoles induced by
vacuolin-1 contain amorphous content,35 which is conspicuously
similar to the morphology of autophagosomes (Fig. 1D). Indeed,
here we found that vacuolin-1 potently inhibited the fusion
between autophagosomes and lysosomes, thereby accumulating
autophagosomes (Fig. 1; Figs. S1–S6). Although vacuolin-1 did
not stop genesis of early endosomes, vacuolin-1 also arrested the
fusion of endosomes and lysosomes, thus stopping the general
endosomal-lysosomal degradation (Fig. 3B–D). In summary,
vacuolin-1 not only induces homotypic fusion to form enlarge
vacuoles but also disrupts general lysosomal functions, e.g.,
autophagy and endocytosis.
RAB5 is required for biogenesis of endolysosomal system.
Here, we found that vacuolin-1 markedly activated RAB5A,
while inhibiting RAB5A activity reversed the effects of vacuolin-
1 (Fig. 4A–F). How vacuolin-1 activates RAB5A remains elusive.
RAB5 is a small monomeric GTPase. The conversion of GDP-
bound RAB5 (inactive form) into the GTP-bound active form is
catalyzed by a guanine nucleotide exchange factor (GEF). The
RAB5-GTP form is subsequently recognized by multiple effec-
tors for its function. The switch of RAB5-GTP back to the
GDP-bound form is not only driven by the intrinsic GTPase
activity of RAB5 but also stimulated by a GTPase-activating pro-
tein (GAP). Multiple RAB5 GEF and GAP have been identi-
fied.46 We speculate that vacuolin-1 could either directly inhibit
RAB5 intrinsic GTPase activity, or activate a RAB5 GEF, or
inhibit a RAB5 GAP, thus keeping RAB5 in a GTP-bound active
state.46 We are currently examining these possibilities.
RAB5A activation is required for vacuolin-1-induced auto-
phagosome-lysosome fusion blockage (Fig. 4B–F). However,
overexpression of RAB5A-CA more potently activated RAB5A
(Fig. 4A) but less efficiently inhibited autophagy compared with
vacuolin-1 (Fig. 4E and F; Fig. S13), hinting that vacuolin-1
regulates other factor besides RAB5A to affect autophagy.
Indeed, vacuolin-1 treatment alkalized lysosomal pH
(Fig. 2D and E) and alkalized pH generally leads to autophagy
arrest.36 Notably, we have recently found that alkalized lysosomal
pH by NAADP-TPCN2-Ca2C signaling prevents the recruit-
ment of RAB7A to autophagosomes, which might be one of the
causes of the blockage of autophagosome-lysosome fusion.36
Likewise, few RFP-RAB7A puncta were colocalized with GFP-
LC3B in vacuolin-1 treated cells, whereas rapamycin markedly
induced the colocalization of RAB7A with GFP-LC3B in control
cells (Fig. S14).
Regarding how vacuolin-1 alkalizes lysosomal pH, obviously,
the nonspecific inhibition of V-ATPase by vacuolin-1 (Fig. 3D)
could directly lead to the increase of lysosomal pH. In addition,
endosomal traffic is important for the function and biogenesis of
lysosome because lysosomes depend on the influx of new compo-
nents. Without incoming endosomal traffic, lysosomes lose their
intact morphology, contents of protons and other ions, and peri-
nuclear localization.47,48 Endosome maturation requires a con-
version from RAB5 to RAB7, and expressing a constitutively
active mutant of RAB5A actually blocks endosome maturation.10
Thus, besides inhibiting V-ATPase, vacoulin-1 could activate
RAB5A to stop endosome maturation, which subsequently com-
promises the biogenesis and function of lysosomes, e.g., pH and
Ca2C content. In addition, many enlarged lysosomes were found
in vacuolin-1 treated cells (Fig. S15),35 which is likely due to
RAB5A activation because expression of RAB5A-DN abolished
it (data not shown). Therefore, it is reasonable to speculate that
V-ATPases might not be able to pump enough protons into the
enlarged lysosomes to maintain the acidic pH; if so, this should
lead to increased lysosomal pH as well. Other than RAB5A and
V-ATPase, whether vacuolin-1 regulates other factors to inhibit
autophagosome-lysosome fusion remains to be determined as
well.
RAB5 family has 3 isoforms, A, B, and C, which are
more than 90% homologous.49 Here, we found that RAB5A
knockdown or expression of RAB5A-DN markedly inhibited
vacuolin-1-induced autophagy arrest (Fig. 4B–F), but had little
effect on starvation-induced autophagy (Figs. S11 and S12).
Consistently, expression of RAB5A-CA also arrested autophagic
flux (Fig. 4E–G; Fig. S13). These data indicate that RAB5A is
not required for autophagy induction. Notably, several studies
report that RAB5 is required for autophagy induction.15,16 The
study by Dou et al. also suggests that RAB5 is only involved in
growth factor starvation, not glucose or amino acid limitation,
induced autophagy.14 It is possible that RAB5 isoforms func-
tion differently in distinct cellular processes, including autoph-
agy.50-53 Further investigations are needed to resolve the
controversy.
Materials and Methods
Antibodies and reagents
The antibodies used were as follows: LC3B (Novus, NB100-
2220), SQSTM1 (Novus, NBP1-48320), CTSL (BD Bioscience,
611084), CTSB (Santa Cruz Biotechnology, SC-13985), EGFR
(Santa Cruz Biotechnology, SC-03), RAB5A (Cell Signaling
Technology, 3547), RAB7 (Cell Signaling Technology, 2094),
LAMP1 (Cell Signaling Technology, 9091), GAPDH antibodys
(Sigma, G8795). Vacuolin-1 (Santa Cruz Biotechnology, SC-
216045), glycyl-L-phenyl-alanine-b-naphthylamide (GPN,
Santa Cruz Biotechnology, SC-252858), BAF (Sigma-Aldrich,
B1793), CQ (Sigma-Aldrich, C6628), rapamycin (Sigma-
Aldrich, R8781), Leup (Sigma-Aldrich, L2884), Fura-2 AM
(Invitrogen, F1221), LysoSensor Green DND-189 (Invitrogen,
L7535), LysoSensor Yellow/Blue DND-160 (Invitrogen,
L7545), DQ green-BSA (Invitrogen, D12050) and Alexa Fluor
488-EGF (Invitrogen, E13345).
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Cell culture
HeLa, MCF-7, A549, and HepG2 cells (ATCC) were main-
tained in DMEM (Invitrogen, 12800-017) plus 10% fetal bovine
serum (Invitrogen, 10270-106) and 100 units/ml of penicillin/
streptomycin (Invitrogen, 15140-122) at 5% CO2 and 37
C.
PC3 cells were maintained in RPMI (Invitrogen, 31800-022)
plus 10% fetal bovine serum (Invitrogen, 10270-106) and 100
units/ml of penicillin/streptomycin (Invitrogen, 15140-122) at
5% CO2 and 37
C.
shRNA and lentivirus production and infection
Two optimal 21-mers were selected in the human RAB5A
gene (Table S1). One 21-mer was selected in the GFP nucleotide
sequence as a control. These sequences were then cloned into the
pLKO.1 vector for expressing shRNA. The shRNA lentivirus
production and infection were performed as described
previously.36
Intracellular Ca2C measurement
Cells were cultured in 24-well plates at the density of 7 £ 104
cells/well in regular medium overnight and were labeled with
4 mM Fura-2 AM in regular HBSS (Invitrogen, 14175-059) at
room temperature for 30 min. The cells were then washed with
calcium-free HBSS containing 2 mM EGTA (Sigma, 3889)
3 times and incubated in the presence or absence of vacuolin-1 at
room temperature for another 10 min. Cells were put on the
stage of an Olympus inverted epifluorescence microscope (Tele-
fon, Germany) and visualized using a 20£ objective. Fluores-
cence images were obtained by alternate excitation at 340 nm
and 380 nm with emission set at 510 nm. Images were collected
by a CCD camera every 3 or 6 s and analyzed by Cell R imaging
software.
Western blot and immunofluorescence staining analyses
Both assays were performed as described previously.36 The
colocalization coefficients of images were quantified by the Ziess
LSM 710 Software, a quantitative colocalization analysis of mul-
tichannel images, as following: (a) correct background (back-
ground correction settings are constant for all images), (b) select
region of interest (ROI), (c) generate histogram of ROI, and (d)
obtain the table of results, including colocalized area, the degree
of colocalization, and colocalization coefficient.
Cell preparation for transmission electron microscopy
(TEM)
Cell preparation for TEM was performed as described
previously.54
MTT cell proliferation assay
Cells were treated in 4 replicates and seeded into 96-well
plates. Following drug treatment, MTT solution (USB Corpora-
tion, 19265) of 20 ml for every 100 ml medium was added to
wells and incubated for 2 h, followed by the addition of 150 mL
of the DMSO solution to each well. The final reaction product, a
purple formazan solution, was detected by a microplate reader
(Techan infinite M200, M€annedorf, Switzerland) for absorbance
at a wavelength of 570 nm and a reference wavelength of
630 nm.
Lysosomal pH measurement
LysoSensor Green DND-189 is commonly used to measure
the pH of acidic organelles, such as lysosomes, which become
more fluorescent in acidic environments. Briefly, cells were
loaded with 1 mM LysoSensor Green DND-189 in prewarmed
regular medium for 20 min at 37C. Then the cells were washed
twice with PBS (Invitrogen, 10010-023) and immediately ana-
lyzed by flow cytometry (collecting FL1 fluorescence and 10,000
cells were collected for each sample) or in a microplate reader
(excitation/emission D 485/530 nm).
Quantification of lysosomal pH was performed using a ratio-
metric lysosomal pH dye, LysoSensor Yellow/Blue DND-160.
The pH calibration curve was generated as described previ-
ously.55 Briefly, cells were trypsinized and labeled with 2 mM
Lysosensor Yellow/Blue DND-160 for 30 min at 37C in regular
medium, and excessive dye was washed out using PBS. The
labeled cells were treated for 10 min with 10 mM monensin
(Sigma, M5273) and 10 M nigericin (Sigma, N7143) in 25 mM
2-(N-morpholino) ethanesulfonic acid (MES) calibration buffer,
pH 3.5–6.0, containing 5 mM NaCl, 115 mM KCl and
1.2 mM MgSO4. Quantitative comparisons were performed in a
96-well plate, and the fluorescence was measured with a micro-
plate reader at 37C. Light emitted at 440 and 535 nm in
response to excitation at 340 and 380 nm were measured, respec-
tively. The ratio of light emitted with 340 and 380 nm excitation
was plotted against the pH values in MES buffer, and the pH cal-
ibration curve for the fluorescence probe was generated from the
plot using Microsoft Excel.
V-ATPase assay
Fifth instar larvae of M. sexta (Lepidoptera, Sphingidae),
weighing 6 to 8 g, were reared under long-day conditions (16 h
of light) at 27C using the gypsy moth diet (MP Biomedicals,
02960292). The purification of the V1VO holoenzyme was per-
formed as previously described.56 Activity assays were performed
in triplicate in a final volume of 160 mL and at a pH of 8.1.
Assays contained 3 mg of purified V1V0 holoenzyme, 50 mM
Tris-MOPS, 3 mM 2-mercaptoethanol, 1 mM MgCl2, 20 mM
KCl, 0.003% C12E10, 20 mM NaCl, and 3 mM TRIS-HCl.
After 10 min of preincubation at 30C, with or without inhibi-
tors, 1 mM Tris-ATP was added and after an incubation for
2 min at 30C the reaction was stopped by freezing the samples
in liquid nitrogen. Inorganic phosphate was determined as previ-
ously described.57
Glutathione S-Transferase (GST) Affinity Isolation Assay
Cells were collected and lyzed in an ice-cold EBC lysis buffer
described above. Lysates were clarified by centrifugation at
13,000 g for 10 min at 4C, and equal amount of protein
(500 mg) from each supernatant fraction was incubated with
30 ml of GST-R5BD bound to the 30 ml glutathione-Sepharose
beads (GE Life Sciences, 17-0756-01) for 1 h at 4C on a rotat-
ing mixer. The beads were subsequently washed and resuspended
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in the standard SDS-sample buffer, boiled, and subjected to
SDS-PAGE (15% gel), followed by immunoblot analysis with
the anti-RAB5 monoclonal antibody.
Statistical analysis
Data were presented as mean § s.e.m. the statistical signifi-
cance of differences was estimated by one-way anova or the Stu-
dent t test. P < 0.05 was considered significant.
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